Neptune Technologies (NEPT +0.00%) suffered a major setback in a tragic explosion to its main production facility in Quebec on Nov. 8. Since then and up until today, trading in the company's shares had been frozen. Markets reacted by sending shares down 24%, reflecting the major production setback from the destroyed facility. The loss will impact the company's main product, a krill-oil-based nutritional supplement. However, one of its subsidiaries has aspirations to compete with fish-oil based pharmaceuticals from companies such as Amarin (AMRN 0.78%) and GlaxoSmithKline (NYSE: GSK).
